.jpg)
.png)
Features
March 13, 2026
2026 ACC/AHA/Multisociety Dyslipidemia Guideline Released
The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia released today...
Read More...March 3, 2026
NLA Highlights New Meta-Analysis Supporting LDL-C Lowering in Primary Prevention
The National Lipid Association (NLA) today announced the publication of a new meta-analysis evaluating the impact of...
Read More...January 29, 2026
NLA Releases an Update on Familial Hypercholesterolemia: An Expert Clinical Consensus
The National Lipid Association released an updated expert clinical consensus on the identification, diagnosis, and...
Read More...January 16, 2026
Dietary Patterns & Nutrition Interventions for Individuals with Dyslipidemia
The mission of the National Lipid Association (NLA) is “to enhance the science and practice of lipidology and promote...
Read More...December 15, 2025
U.S. Food and Drug Administration Approves LIB Therapeutics’ LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
CINCINNATI, Ohio – December 15, 2025 – LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company...
Read More...